# Multiple CAR-T Cell Therapy Targeting AML

> **NCT04010877** · PHASE1,PHASE2 · RECRUITING · sponsor: **Shenzhen Geno-Immune Medical Institute** · enrollment: 10 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **BIOLOGICAL:** CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells

## Key facts

- **NCT ID:** NCT04010877
- **Lead sponsor:** Shenzhen Geno-Immune Medical Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-01
- **Primary completion:** 2028-07-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04010877

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04010877, "Multiple CAR-T Cell Therapy Targeting AML". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04010877. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*